Paper37490802
Guizhi Shaoyao Zhimu granules attenuate bone destruction in mice with collagen-induced arthritis by promoting mitophagy of osteoclast precursors to inhibit osteoclastogenesis.
Yao H and 9 others. Phytomedicine, 2023. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Guizhi Shaoyao Zhimu granules attenuate bone destruction in mice with collagen-induced arthritis by promoting mitophagy of osteoclast precursors to inhibit osteoclastogenesis. Papers, record 37490802. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37490802
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Guizhi Shaoyao Zhimu granules attenuate bone destruction in mice with collagen-induced arthritis by promoting mitophagy of osteoclast precursors to inhibit osteoclastogenesis.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Arthritis, Experimental | Major topic |
| Arthritis, Rheumatoid | Major topic |
| Bone Resorption | Major topic |
| Mice | |
| Rats | |
| Animals | |
| Osteoclasts | |
| Osteogenesis | |
| Mitophagy | |
| Mice, Inbred DBA | |
| Protein Kinases | |
| RANK Ligand |
Source PubMed
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42959626 | Research progress of mitophagy and its targeted therapeutic strategies in rheumatoid arthritis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42959626 | PubMed |
| 42439331 | Mechanistic Study of Yibi Decoction in Treating Rheumatoid Arthritis via Modulating the JAK2/STAT3 Signaling Pathway. | Endocr Metab Immune Disord Drug Targets | 2026 | https://conductscience.org/library/papers/42439331 | PubMed |
| 42198392 | Revealing the Pharmacological Mechanism of Tibetan Medicine Wugeng San in Treating Rheumatoid Arthritis Through an Integrated Strategy of Chemical Composition Analysis, Network Pharmacology, Machine Learning, and In Vivo Experiments. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42198392 | PubMed |
| 42173965 | The miR4261/PAMM axis in multiple myeloma promotes bone resorption. | Sci Rep | 2026 | https://conductscience.org/library/papers/42173965 | PubMed |
| 41752211 | A Study on the Treatment of Rheumatoid Arthritis Using a Novel GelMA-HAMA Dual-Network Hydrogel Microneedle Loaded with MTX-NCs in Combination with Adalimumab. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41752211 | PubMed |
| 41652638 | NRAS and SREBF1 identified as mitophagy-associated risk genes for rheumatoid arthritis through interpretable machine learning and experimental validation studies. | BMC Rheumatol | 2026 | https://conductscience.org/library/papers/41652638 | PubMed |
| 41035029 | Bioinspired catalytic nanogel as an inflammatory cascade-targeted therapeutic for rheumatoid arthritis. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/41035029 | PubMed |
| 40821693 | Mitochondrial Quality Control in Health and Disease. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/40821693 | PubMed |
| 40728722 | An emerging role of mitochondrial quality control in bone metabolism: from molecular mechanisms to targeted therapeutic interventions. | Cell Mol Life Sci | 2025 | https://conductscience.org/library/papers/40728722 | PubMed |
| 39741752 | Important Role of Mitochondrial Dysfunction in Immune Triggering and Inflammatory Response in Rheumatoid Arthritis. | J Inflamm Res | 2024 | https://conductscience.org/library/papers/39741752 | PubMed |
| 39524718 | Risperidone accelerates bone loss in mice models of schizophrenia by inhibiting osteoblast autophagy. | Heliyon | 2024 | https://conductscience.org/library/papers/39524718 | PubMed |
| 39450183 | Cytoplasmic DNA and AIM2 inflammasome in RA: where they come from and where they go? | Front Immunol | 2024 | https://conductscience.org/library/papers/39450183 | PubMed |
| 39376556 | Overview of mechanisms and novel therapies on rheumatoid arthritis from a cellular perspective. | Front Immunol | 2024 | https://conductscience.org/library/papers/39376556 | PubMed |
| 39367607 | Bone-protective effects of neutralizing angiopoietin-like protein 4 monoclonal antibody in rheumatoid arthritis. | Mol Ther | 2024 | https://conductscience.org/library/papers/39367607 | PubMed |
| 38693741 | Deciphering the Pharmacological Mechanisms of Wen-Jing-Zhi-Tong Decoction in Treating Primary Dysmenorrhea by UPLC-Q-Exactive- Orbitrap-MS/MS with GC-MS and Network Pharmacology. | Comb Chem High Throughput Screen | 2025 | https://conductscience.org/library/papers/38693741 | PubMed |
| 38671436 | PTEN: an emerging target in rheumatoid arthritis? | Cell Commun Signal | 2024 | https://conductscience.org/library/papers/38671436 | PubMed |
| 38545550 | The protective effect of traditional Chinese medicine Jinteng Qingbi granules on rats with rheumatoid arthritis. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38545550 | PubMed |
| 37815897 | The Emerging Role of the Mitochondrial Respiratory Chain in Skeletal Aging. | Aging Dis | 2024 | https://conductscience.org/library/papers/37815897 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37490802
GET https://conductscience.org/api/papers/v1/37490802/authors